News & Events

Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist

Posted by on Jul 16, 2015 in News | 0 comments

Avineuro LLC announced completion of phase II pilot clinical study of AVN-211, a proprietary orally-bioavailable molecule of a 5-HT6 receptor antagonist. In a multicenter double-blind randomized placebo-controlled pilot study of efficacy and safety of AVN-211 for amplifying the effects of antipsychotic drugs in patients with schizophrenia in a condition of incomplete remission receiving stable antipsychotic therapy, 80 patients were randomized to receive 8 mg of AVN-211 or Placebo QD for 6 weeks (initial dose 4 mg of AVN-211 was prescribed QD...

read more

AllaChem, LLC Сompletes Phase Ib/IIa Clinical Study with AV4025, an HCV NS5A Inhibitor

Posted by on Dec 15, 2014 in News | 0 comments

December 14, 2014. AllaChem, LLC, announced today a successful completion of phase Ib/IIa clinical study with AV4025, a proprietary orally-bioavailable small molecule that blocks HCV genome replication by targeting viral non-structural protein NS5A. In a double-blind, placebo-controlled, randomized study of safety, tolerability, pharmacokinetics and antiviral activity of AV-4025 in HCV-infected patients, HCV- infected, treatment-naive subjects were randomized to receive 20 or 40 mg AV-4025 or placebo QD for 3 days (up to 10 subjects per...

read more

Alla Chem, LLC Announces Start of Phase Ib Proof-Of-Concept Clinical Study of AVR560, an HCV entry inhibitor, for the Treatment of Chronic Hepatitis C Infection

Posted by on May 15, 2014 in News | 0 comments

Hallandale Beach, Fl –May 15, 2014 — Alla Chem, LLC, announces today start of phase 1b clinical study of AVR560, an investigational, orally bioavailable HCV entry inhibitor, currently in clinical development for the treatment of chronic HCV infection. In this randomized, double-blind, placebo-controlled, multicentre study of safety, tolerability, pharmacokinetics and antiviral activity of AVR560 in HCV-infected patients, HCV- infected, treatment-naive subjects will be randomized to receive 100 or 150 mg AVR560 or placebo QD for 14 days (up to...

read more

Alla Chem, LLC Announces Initiation of Phase I Clinical Studies of ONC1-13B, a New Effective Anti-Androgen for the Treatment of Prostate Cancers

Posted by on May 14, 2014 in News | 0 comments

Hallandale Beach, Fl –May 14, 2014 — Alla Chem, LLC announces initiation of Phase 1 clinical study of ONC1-13B in patients with metastatic Castration Resistant Prostate Cancer (mCRPC). ONC1-13B is a next in-class small molecule anti-androgen for the treatment of Prostate Cancers. In preclinical studies, it was shown that ONC1-13B efficiently inhibits androgen receptor signaling pathway by preventing binding to androgens, blocking its nuclear translocation and transcriptional co-activator complex formation (A. V. Ivachtchenko et al....

read more

Alla Chem, LLC Announces Start of Phase Ib Clinical Study of AV4025, an NS5A inhibitor, for the Treatment of Chronic Hepatitis C Infection

Posted by on May 12, 2014 in News | 0 comments

Hallandale Beach, Fl –May 12, 2014 — Alla Chem, LLC (Hallandale Beach, Fl), announces today start of phase 1b clinical study of AV4025, an investigational, orally bioavailable HCV NS5A inhibitor, currently in clinical development for the treatment of chronic HCV infection. In this randomized, double-blind, placebo-controlled, multicentre study of safety, tolerability, pharmacokinetics and antiviral activity of AV-4025 in HCV-infected patients, HCV- infected, treatment-naive subjects will be randomized to receive 20 or 40 mg AV-4025 (once...

read more

AllaChem completes phase 1a clinical study with AV4025, an HCV NS5A inhibitor

Posted by on Oct 7, 2013 in News | 0 comments

October 7 , 2013. AllaChem, LLC, announced today a successful completion of phase 1a clinical study with AV4025, a proprietary orally-bioavailable small molecule that blocks HCV genome replication by targeting viral non-structural protein NS5A. In a double-blind, placebo-controlled, single ascending oral dose study of AV4025 safety and tolerability in healthy volunteers, each dose cohort (10 subjects per cohort) received a single dose of 10, 20, or 40 mg AV54025, or placebo (drug:placebo ratio 4:1). The drug was safe and well-tolerated, no...

read more

Alla Chem, LLC Announces the Completion of Pre-Clinical Studies With ONC1-13B, a New Effective Anti-Androgen for the Treatment of Prostate and Breast Cancers

Posted by on Aug 5, 2013 in News | 0 comments

Hallandale Beach, Fl – July 28, 2013 – Alla Chem, LLC announced today the completion of pre-clinical studies with ONC1-13B, a next in-class small molecule androgen receptor inhibitor for the treatment of prostate and breast cancers. The results will be reported at the 3rd World Congress on Cancer Science & Therapy, October 21-23, 2013, in San Francisco . The submission package for the phase I/II clinical studies is under review by the Russian Regulatory Agencies. The phase I / II clinical studies will be conducted in 12-24...

read more

Alla Chem, LLC Announces the Beginning of Phase I Clinical Studies of AV4025, a Potent Small Molecule for the Treatment of Chronic Hepatitis C Infection

Posted by on Aug 5, 2013 in News | 0 comments

August 5, 2013 — AllaChem, LLC announces the beginning of Phase I clinical studies of AV4025, a potent small molecule for the treatment of chronic hepatitis C infection. Hallandale Beach, Fl – July 25, 2013 – Alla Chem, LLC announced today the initiation of phase I clinical studies with AV4025, a next in-class small molecule HCV NS5A Inhibitor for the treatment of chronic hepatitis C infection. A double-blind, placebo-controlled, single ascending dose (10, 20 and 40 mg) study will evaluate safety, tolerability and pharmacokinetics...

read more